Clinical Trials Logo

Heart Transplant Infection clinical trials

View clinical trials related to Heart Transplant Infection.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05064462 Active, not recruiting - Virus Clinical Trials

TTV Viral Load in Heart Transplant Recipients

TTVCoeur
Start date: March 3, 2022
Phase:
Study type: Observational

This prospective, multicenter, non-interventional trial aims to study the association between TTV viral load and the occurrence of rejection or infection during the first year after transplantation. The TTV viral loads, taken once a month during the first year after the transplant, will be measured at the end of the study.

NCT ID: NCT04904614 Active, not recruiting - Neutropenia Clinical Trials

Letermovir Use in Heart Transplant Recipients

Start date: October 1, 2021
Phase: Phase 4
Study type: Interventional

This is an open label trial in which letermovir will be given as prophylaxis for the prevention of CMV infection and disease to all heart transplants who are at risk for cytomegalovirus. The study will compare a 30 patient prospective cohort to a retrospective cohort of 374 heart transplant recipients for the rates of neutropenia. In addition, the tolerability of letermovir will be assessed in this population.

NCT ID: NCT03924219 Active, not recruiting - Clinical trials for Kidney Transplant Infection

CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients

Start date: June 3, 2019
Phase:
Study type: Observational

CMV infection and disease remain a significant clinical challenge for pediatric solid organ transplant (SOT) recipients. Current prevention strategies are limited to prophylaxis in which antiviral medication is administered for a period of several months or preemption in which close monitoring of CMV viral load from the peripheral blood is performed and treatment is initiated when CMV is detected. Each of these strategies has risks, costs, and limitations associated with it. Recently, assays for measurement of an individual patient's CMV immunity have been developed and are clinically available. One of these is the Viracor CMV T cell Immunity Panel. This flow cytometry based assay is performed on peripheral blood and measures cytokine release in response to CMV antigen stimulation by flow cytometry. The thresholds for this assay that confer protection against CMV infection in pediatric SOT recipients are not known. Defining CMV-specific cell mediated immune response thresholds that confer protection against CMV reactivation could inform patient specific durations of antiviral prophylaxis or pre-emptive surveillance testing. Therefore, the objective of this study is to quantify CMVresponsive T lymphocyte populations by flow cytometry (Viracor CMV T cell Immunity Panel) in pediatric heart, kidney, and liver transplant recipients within the first year of transplantation and to investigate potential threshold values that correlate with protection against CMV infection (DNAemia).

NCT ID: NCT03386539 Active, not recruiting - Clinical trials for Chronic Kidney Diseases

Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score

TEAMMATE
Start date: January 29, 2018
Phase: Phase 3
Study type: Interventional

The TEAMMATE Trial will enroll 210 pediatric heart transplant patients from 25 centers at 6 months post-transplant and follow each patient for 2.5 years. Half of the participants will receive everolimus and low-dose tacrolimus and the other half will receive tacrolimus and mycophenolate mofetil. The trial will determine which treatment is better at reducing the cumulative risk of coronary artery vasculopathy, chronic kidney disease and biopsy proven-acute cellular rejection without an increase in graft loss due to all causes (e.g. infection, PTLD, antibody mediated rejection).